Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL708837 | 0.98 | HRH1 (0.56) | HRH1LOXL2HRH3HRH4NAAA | |
| Hydrochloric Acid SCHEMBL8329183 | 0.95 | HRH1 (0.54) | HRH1LOXL2HRH3HRH4NAAA | |
| Bromide SCHEMBL7919282 | 0.93 | HRH1 (0.57) | HRH1LOXL2HRH3HRH4NAAA | |
| SCHEMBL10376892 | 0.91 | HRH1 (0.59) | HRH1LOXL2HRH3HRH4NAAA | |
| SCHEMBL11446555 | 0.88 | HRH1 (0.63) | HRH1LOXL2HRH3HRH4NAAA | |
| SCHEMBL10663683 | 0.88 | HRH1 (0.63) | HRH1LOXL2HRH3HRH4NAAA | |
| SCHEMBL7740622 | 0.88 | HRH1 (0.63) | HRH1LOXL2HRH3HRH4NAAA | |
| Bromide SCHEMBL3395799 | 0.85 | LOXL2 (0.54) | HRH1LOXL2HRH3HRH4NAAA | |
| SCHEMBL4057377 | 0.82 | — | — | |
| SCHEMBL351920 | 0.82 | HRH1 (0.65) | HRH1LOXL2HRH3HRH4NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-8329729-B2 | Quinuclidine derivatives as muscarinic M3 receptor antagonists | ASTRAZENECA AB (SE) | 2012-12-11 | — | — | US | disclosed |
| CN-101123964-B | G-protein coupled receptor (GPR116) agonists and pharmaceutical compositions comprising the same | PROSIDION LTD | 2012-11-28 | — | — | CN | disclosed |
| US-20110172237-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA UK LIMITED (GB) | 2011-07-14 | — | — | US | disclosed |
| EP-2300464-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009138707-A9 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009153536-A1 | 1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | PROSIDION LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| CN-101123964-A | G-protein coupled receptor (GPR116) agonists and their use for the treatment of obesity and diabetes | PROSIDION LTD (GB) | 2008-02-13 | — | — | CN | disclosed |
| EP-1838311-A1 | G-PROTEIN COUPLED RECEPTOR (GPR116) AGONISTS AND USE THEREOF FOR TREATING OBESITY AND DIABETES | Prosidion Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006067531-A1 | G-PROTEIN COUPLED RECEPTOR (GPR116) AGONISTS AND USE THEREOF FOR TREATING OBESITY AND DIABETES | PROSIDION LTD (GB) | 2006-06-29 | — | — | WO | disclosed |
| EP-0223344-B1 | GAMMA-CARBOLINES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-08-22 | — | — | EP | disclosed |
| EP-0223344-A1 | Gamma-carbolines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-05-27 | — | — | EP | disclosed |
| US-4029788-A | ANTIAMEBIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | GPR119, GCGR, GPR65 | HRH1 1727/4885LOXL2 1767/4885HRH3 2286/4885 |
| US-20110172237-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | HRH1 113/4885LOXL2 3137/4885HRH3 49/4885 |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM5 | HRH1 193/4885LOXL2 3708/4885HRH3 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.